AiM Medical Robotics Adds Surgical Robotics Pioneer Yulun Wang to Board as It Prepares Commercial Launch

New updates have been reported about AiM Medical Robotics.

AiM Medical Robotics has appointed surgical-robotics pioneer Yulun Wang, PhD, to its Board of Directors, strengthening governance as the company moves from first-in-human studies toward regulatory clearance and commercialization of its MRI-compatible stereotactic neurosurgery robot. The platform targets an estimated $10 billion addressable market in neurostimulation electrode placement for Parkinson’s disease, depression, tremors, tumor ablations, and other functional neurosurgical procedures.

Wang, founder of Computer Motion and principal architect of AESOP and the ZEUS robotic surgical system that enabled the first transatlantic remote surgery, brings four decades of experience turning complex engineering concepts into scaled, clinically adopted products and successful exits. AiM CEO and founder Gregory Fischer said Wang’s decision to join the board validates AiM’s technology and strategy and will be critical as the company advances toward broader clinical deployment and commercial release.

The company’s MRI-guided robotic platform is designed to improve precision, reproducibility, and workflow efficiency while integrating into existing neurosurgical practices and reimbursement frameworks. Wang highlighted the technical differentiation and commercial potential of AiM’s architecture, citing strong alignment between the company’s disciplined development approach and the requirements for long-term value creation.

Chief Medical Officer Jonathan Sackier noted that Wang’s background at Computer Motion and InTouch Health will reinforce AiM’s focus on capital efficiency and clinically grounded execution, supporting both investor confidence and adoption by neurosurgeons and health systems. Strategically, AiM is emphasizing clear regulatory pathways, capital-light development, and scalability to position its system as a platform technology across multiple brain procedures.

Headquartered in Worcester, Massachusetts, AiM is developing a compact, portable MRI-compatible robot that enables continuous real-time visualization during surgery, aiming to reduce variability, improve safety, and shorten procedure times. Looking ahead, the company plans to integrate artificial intelligence to create an intelligent surgical ecosystem that learns from real-world data, optimizes workflows, and provides predictive insights to surgeons in real time.

For executives and investors, Wang’s appointment signals board-level reinforcement ahead of key regulatory and commercial inflection points, with potential implications for future financing, partnerships, and eventual strategic outcomes. AiM cautions that its device remains in development and subject to regulatory, clinical, manufacturing, and market risks, and forward-looking statements about timelines, market acceptance, and financial performance may differ from actual results.